Stage IB Breast Cancer AJCC v7

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N1mi: Nodal micrometastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


breast rhabdomyosarcoma

category: biolink:Disease biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: A malignant mesenchymal tumor with skeletal muscle differentiation affecting the breast.


Breast Cancer by AJCC v7 Stage

description: A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 7th edition.


Stage IIB Breast Carcinoma

description: Stage IIB includes: (T2, N1, M0); (T3, N0, M0).  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 6th and 7th Eds.)


Anatomic Stage IB Breast Cancer AJCC v8

description: Stage IB includes: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Breast Ductal Carcinoma In Situ and Lobular Carcinoma

description: A breast carcinoma characterized by the presence of a ductal carcinoma in situ component and an in situ or invasive lobular carcinomatous component.


name: Recurrent Breast Ductal Carcinoma In Situ

description: The reemergence of breast ductal carcinoma in situ after a period of remission.


name: Breast Ductal Carcinoma In Situ, Non-Comedo Type

description: Breast ductal carcinoma in situ characterized by the presence of sheets of tumor cells without evidence of central necrosis or cell death.


name: Locally Advanced Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Invasive Breast Lobular Carcinoma, Signet Ring Variant

description: An invasive lobular carcinoma characterized by the presence of malignant epithelial cells with large intracytoplasmic lumina that cause displacement of the nuclei towards one pole of the cells.


name: Prognostic Stage I Breast Cancer AJCC v8

description: Stage I includes: IA: (T1, N0, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T1, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (T0-1, N1mi, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T0-1, N1mi, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Any); (MultiGene Panel-Oncotype Dx Recurrence Score Less Than 11, T1-2, N0, M0, G1-3, HER2 Status: Negative, ER Status: Positive, PR Status: Any); IB: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Anatomic Stage IIIA Breast Cancer AJCC v8

description: Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Breast Squamous Cell Carcinoma

description: A squamous cell carcinoma that arises from the breast parenchyma and has metastasized to other anatomic sites.


Invasive papillary breast carcinoma

description: An invasive breast carcinoma characterized by the presence of papillary structures.


name: adenocarcinoma of breast with spindle cell metaplasia

description: An invasive adenocarcinoma of the breast usually affecting post-menopausal women, characterized by extensive spindle cell metaplasia of the neoplastic glandular cells.


name: Recurrent Progesterone Receptor-Positive Breast Carcinoma

description: The reemergence of progesterone receptor-positive breast carcinoma after a period of remission.


Metastatic Breast Carcinoma in the Skin

description: A carcinoma that arises from the breast and has metastasized to the skin.


Unresectable HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that is not amenable to surgical resection.


name: Ductal Carcinoma In Situ with Microinvasion

description: Invasive breast carcinoma measuring 1 mm or less in size.


Early Stage Breast Carcinoma

description: Breast carcinoma that has not spread beyond the breast and the axillary lymph nodes.


Anatomic Stage IV Breast Cancer AJCC v8

description: Stage IV includes: Any T, Any N, M1. M1: Distant metastases detected by clinical and radiographic means and/or histologically proven metastases larger than 0.2 mm. (AJCC 8th ed.)


Unresectable Breast Adenocarcinoma

description: A breast adenocarcinoma that is not amenable to surgical resection.


name: Unresectable Breast Inflammatory Carcinoma

description: Inflammatory breast carcinoma that is not amenable to surgical resection.


Invasive Female Breast Carcinoma

description: An invasive carcinoma that arises from the breast in females.


name: Refractory HER2-Negative Breast Carcinoma

description: A HER2-negative breast adenocarcinoma that is resistant to treatment.


name: Breast Carcinoma with Chondroid Metaplasia

description: An invasive carcinoma of the breast showing differentiation towards cartilaginous structures.


Metastatic HER2-Low Breast Carcinoma

description: A HER2-low breast adenocarcinoma that has spread from its original site of growth to another anatomic site.


Hereditary Male Breast Carcinoma

description: Breast carcinoma that has developed in male relatives of patients with history of breast carcinoma.


Recurrent Breast Paget Disease

description: The reemergence of Paget disease of the breast after a period of remission.


name: Early Stage Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that has not spread beyond the breast or axillary lymph nodes.


Locally Advanced Breast Adenocarcinoma

description: Breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Childhood Breast Carcinoma

description: A rare breast carcinoma that occurs during childhood.


name: Breast Ductal Carcinoma with Squamous Metaplasia

description: An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the ductal carcinomatous component.


name: Metastatic Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Stage IA Breast Cancer AJCC v7

description: Stage IA includes: T1, N0, M0.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  N0: No regional lymph node metastasis.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


name: Invasive Breast Lobular Carcinoma, Pleomorphic Variant

description: A grade II invasive lobular carcinoma of the breast, characterized by the presence of neoplastic cells with large and atypical nuclei.


Breast Cancer by AJCC v8 Anatomic Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. This staging system should only be used in global regions where biomarker tests are not routinely available. (from AJCC 8th Ed.)


Breast cancer recurrent

description: The reemergence of carcinoma in the breast after a period of remission.


Breast Mixed Carcinoma

description: An invasive breast carcinoma characterized by the presence of more than one malignant epithelial histologic pattern.


name: Breast Carcinoma with Melanotic Features

description: A very rare primary malignant tumor of the breast, characterized by an invasive breast carcinoma that co-exists with a melanoma component.  The vast majority of melanotic tumors that affect the breast are metastatic melanomas that originate in extra-mammary sites.


name: Breast Paget Disease without Invasive Carcinoma

description: Paget disease involving the skin overlying the mammary gland, without accompanying invasive ductal or lobular breast carcinoma.


Refractory Breast Carcinoma

description: Breast carcinoma that does not respond to treatment.


Breast Cancer by AJCC v8 Stage

description: A term that refers to the staging of breast cancer, following the rules of the TNM AJCC v8 classification system. It applies to invasive (infiltrating) carcinoma of the breast and ductal carcinoma in situ of the breast. It does not apply to breast sarcoma, phyllodes tumor, and breast lymphoma. (from AJCC 8th Ed.)


name: Breast Classic Lobular Carcinoma In Situ Type A

description: Breast classic lobular carcinoma in situ characterized by the presence of neoplastic cells with uniform nuclei.


name: Unresectable Triple-Negative Breast Carcinoma

description: Triple-negative breast carcinoma that is not amenable to surgical resection.


Advanced Breast Carcinoma

description: Breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.


name: Inflammatory carcinoma of breast stage IV

description: An inflammatory carcinoma of the breast that has spread to other anatomic sites.


name: Metastatic HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that has spread from the original site of growth to another anatomic site.


name: Prognostic Stage IIIB Breast Cancer AJCC v8

description: Stage IIIB includes: (T2, N1, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T2, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N0, M0, G1-2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T3, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-2, N2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-2, N2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T3, N1-2, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T3, N1-2, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (T4, N0-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T4, N0-2, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G1, HER2 Status: Positive, ER Status: Any, PR Status: Any); (Any T, N3, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (Any T, N3, M0, G3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Breast Cancer by AJCC v6 Stage

description: A term that refers to the staging of breast cancer according to the American Joint Committee on Cancer, 6th edition.


Recurrent Breast Lymphoma

description: The reemergence of breast lymphoma after a period of remission.


name: Breast Ductal Carcinoma In Situ, Low Grade

description: Breast ductal carcinoma in situ characterized by the presence of small, monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. The nuclei are uniform and mitotic figures are rare.


Locally Advanced Breast Carcinoma

description: A breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


Contralateral Breast Carcinoma

description: Breast carcinoma that develops in the opposite breast of a patient with an already diagnosed primary breast carcinoma.


name: Prognostic Stage IB Breast Cancer AJCC v8

description: Stage IB includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-3, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T1, N1, M0, G1-2, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N1, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1-2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G2, HER2 Status: Positive, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


name: Metastatic Squamous Cell Carcinoma in the Breast

description: A squamous cell carcinoma that has spread to the breast from another anatomic site.


name: Prognostic Stage IIA Breast Cancer AJCC v8

description: Stage IIA includes: (T1, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T1, N0, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G2, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1mi, M0, G3, HER2 Status: Negative, ER Status: Negative, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T0-1, N1, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T0-1, N1, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T2, N0, M0, G1, HER2 Status: Positive, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1-2, HER2 Status: Positive, ER Status: Negative, PR Status: Any); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Negative); (T2, N0, M0, G1, HER2 Status: Negative, ER Status: Negative, PR Status: Positive); (T2, N0, M0, G3, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T0-2, N2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive); (T3, N1-2, M0, G1, HER2 Status: Negative, ER Status: Positive, PR Status: Positive). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N1mi: Micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. G1: Low combined histologic grade (favorable); SBR score of 3-5 points. G2: Intermediate combined histologic grade (moderately favorable); SBR score: 6-7 points. G3: High combined histologic grade (unfavorable); SBR score of 8-9 points. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Oligometastatic Breast Carcinoma

description: Breast carcinoma that has metastasized to a limited number of sites.


Encapsulated Breast Papillary Carcinoma

description: Breast carcinoma characterized by the presence of fine fibrovascular stalks covered by neoplastic epithelial cells of low or intermediate nuclear grade, typically present within a cystic space and surrounded by a fibrous capsule. There are usually no myoepithelial cells along the papillae or at the periphery of the lesion. (WHO 2019)


name: Breast Carcinoma Metastatic in the Brain

description: A carcinoma that has spread to the brain from its original site in the breast, through the hematogenous route.


name: Encapsulated Breast Papillary Carcinoma with Invasion

description: Encapsulated breast papillary carcinoma characterized by the presence of neoplastic elements that permeate beyond the fibrous capsule with an irregular infiltrative appearance. (WHO 2019)


name: Breast Carcinoma with Osteoclast-Like Stromal Giant Cells

description: An invasive breast adenocarcinoma characterised by the presence of non-neoplastic stromal osteoclastic giant cells.  The carcinomatous component is usually an invasive ductal carcinoma, although all other breast adenocarcinoma subtypes have also been described.  The prognosis depends on the characteristics of the adenocarcinomatous component, and is not related to the presence of the giant cells.


Grade 2 Invasive Breast Carcinoma

description: A moderately differentiated invasive breast carcinoma.


name: Anatomic Stage III Breast Cancer AJCC v8

description: Stage III includes: IIIA: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0); IIIB: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0); IIIC: (Any T, N3, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. T2: Tumor measuring more than 20 mm, but not more than 50 mm in greatest dimension. T3: Tumor measuring more than 50 mm in greatest dimension. T4: Tumor of any size with direct extension to the chest wall and/or to the skin (ulceration or macroscopic nodules); invasion of the dermis alone does not qualify as T4. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1: Tumor with micrometastases; or metastases in 1-3 axillary lymph nodes; and/or clinically negative internal mammary nodes with micrometastases or macrometastases by sentinel lymph node biopsy. N2: Tumor with metastases in 4-9 axillary lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the absence of axillary lymph node metastases. N3: Tumor with metastases in 10 or more axillary lymph nodes; or in infraclavicular (level III axillary) lymph nodes; or positive ipsilateral internal mammary lymph nodes by imaging in the presence of one or more positive level I, II axillary lymph nodes; or in more than three axillary lymph nodes and micrometastases or macrometastases by sentinel lymph node biopsy in clinically negative ipsilateral internal mammary lymph nodes; or in ipsilateral supraclavicular lymph nodes. M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Anatomic Stage I Breast Cancer AJCC v8

description: Stage I includes: IA: (T1, N0, M0); IB: (T0, N1mi, M0); (T1, N1mi, M0). T0: No evidence of primary tumor. T1: Tumor measuring 20 mm or less in greatest dimension. N0: No regional lymph node metastasis is identified or isolated tumor cell clusters (ITCs) are identified only. N1mi: Tumor with micrometastases (approximately 200 cells, larger than 0.2 mm, but none larger than 2.0 mm). M0: No clinical or radiographic evidence of distant metastases. Imaging studies are not required to assign the M0 category. (AJCC 8th ed.)


Metastatic Malignant Breast Neoplasm

description: A malignant breast neoplasm that has metastasized to another anatomic site.


Resectable Breast Carcinoma

description: Breast carcinoma that is amenable to surgical resection.


name: Low Grade Breast Mucoepidermoid Carcinoma

description: A slow growing mucoepidermoid carcinoma that arises from the breast. It is characterized by the presence of keratinization in the neoplastic squamous cells and lumina formation by glandular neoplastic cells. Complete excision may be curative.


name: Metastatic BRCA-Associated Breast Carcinoma

description: BRCA-associated breast carcinoma that has spread to another anatomic site.


Recurrent Lobular Breast Carcinoma

description: The reemergence of lobular breast carcinoma after a period of remission.


name: Estrogen Receptor-Positive Breast Carcinoma

description: Breast adenocarcinoma that is positive for estrogen receptors.


name: Invasive Breast Lobular Carcinoma with Extracellular Mucin

description: A rare variant of invasive breast lobular carcinoma characterized by the presence of pools of extracellular mucin in which groups of floating lobular carcinoma cells are identified.


name: Breast Ductal Carcinoma In Situ, Intermediate Grade

description: Breast ductal carcinoma in situ characterized by the presence of monomorphic neoplastic cells that form cribriform, micropapillary, or solid patterns. Intraluminal necrosis is present in some ducts. Ducts that contain neoplastic cells with occasional nucleoli and coarse chromatin may also be present.


name: Recurrent Hormone Receptor-Positive Breast Carcinoma

description: The reemergence of hormone receptor-positive breast adenocarcinoma after a period of remission.


name: adenocarcinoma of breast with squamous metaplasia

description: An invasive breast carcinoma characterized by the presence of a predominant squamous cell component that is admixed with the adenocarcinoma component.


name: Recurrent Triple-Negative Breast Carcinoma

description: The reemergence of triple-negative breast carcinoma after a period of remission.


name: Metastatic Progesterone Receptor-Positive Breast Carcinoma

description: Progesterone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.


Breast Neuroendocrine Carcinoma

description: A neuroendocrine carcinoma arising from the breast. It is classified as small cell or large cell neuroendocrine carcinoma.


name: Locally Advanced HER2-Positive Breast Carcinoma

description: HER2-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


name: Metastatic Hormone Receptor-Negative Breast Carcinoma

description: Hormone receptor-negative breast carcinoma that has spread from its original site of growth to another anatomic site.


Metastatic Breast Ductal Carcinoma

description: A ductal breast carcinoma that has spread from the original site of growth to another anatomic site.


name: Breast Carcinoma Metastatic in the Central Nervous System

description: A carcinoma that has spread to the central nervous system from its original site in the breast, through the hematogenous route.


Recurrent Breast Tubular Carcinoma

description: The reemergence of breast tubular carcinoma after a period of remission.


Stage IIIA Breast Carcinoma

description: Stage IIIA includes: (T0, N2, M0); (T1, N2, M0); (T2, N2, M0); (T3, N1, M0); (T3, N2, M0).  T0: No evidence of primary tumor.  T1: Tumor 20 mm or less in greatest dimension.  T1 includes T1mi. T1mi: Tumor 1 mm or less in greatest dimension.  T2: Tumor more than 20 mm but not more than 50 mm in greatest dimension.  T3: Tumor more than 50 mm in greatest dimension.  N1: Metastasis to movable ipsilateral level I, II axillary lymph node(s).  N2: Metastases in ipsilateral level I, II axillary lymph nodes that are clinically fixed or matted; or in clinically detected ipsilateral internal mammary nodes in the absence of clinically evident axillary lymph node metastases.  M0: No clinical or radiographic evidence of distant metastasis.  M0 includes M0(i+).  (AJCC 7th Ed.)


small cell carcinoma of breast

description: A poorly differentiated neuroendocrine carcinoma that arises from the breast.  It is characterized by the presence of small neuroendocrine cells and high mitotic activity.


name: Locally Advanced Hormone Receptor-Positive Breast Carcinoma

description: Hormone receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.


gamma-taxilin

A protein that is a translation product of the human TXLNG gene or a 1:1 ortholog thereof.


gamma-taxilin isoform h1 (human)

A gamma-taxilin (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NUQ3-1.


gamma-taxilin isoform h2 (human)

A gamma-taxilin (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NUQ3-2.


gamma-taxilin cysteinylated 1 (human)

A gamma-taxilin (human) that has been cysteinylated on the residue at the position equivalent to Cys-160 of the amino acid sequence represented by UniProtKB:Q9NUQ3-1. Example: UniProtKB:Q9NUQ3-1, Cys-160, MOD:00765.


name: osteopetrosis-associated transmembrane protein 1 methylated 1 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been methylated on the residue at the position equivalent to Cys-199 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Cys-199, MOD:00660.


name: osteopetrosis-associated transmembrane protein 1 deaminated 2 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-163 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Asn-163, MOD:00684.


name: osteopetrosis-associated transmembrane protein 1, signal peptide removed form (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has had the signal peptide removed. UniProtKB:Q86WC4, 32-334.


name: osteopetrosis-associated transmembrane protein 1 deaminated 1 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-194 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Asn-194, MOD:00684.


name: osteopetrosis-associated transmembrane protein 1 cysteinylated 1 (human)

description: An osteopetrosis-associated transmembrane protein 1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-199 of the amino acid sequence represented by UniProtKB:Q86WC4. UniProtKB:Q86WC4, Cys-199, MOD:00765.


A pyrazine substituted by a hydroxy group at positions 2 and 5.


arenesulfonic acid

Organic derivatives of sulfonic acid in which the sulfo group is linked directly to carbon of an aryl group.


indigo carmine

A member of the class of indolones obtained by formal 2,2'-oxidative coupling of two molecules of 3-oxo-2,3-dihydroindole-5-sulfonic acids.


lissamine fast yellow (acid form)

An arenesulfonic acid that is 2,5-dichloro-4-(pyrazol-1-yl)benzene-1-sulfonic acid in which the pyrazole ring is substituted by methyl, (4-sulfophenyl)diazenyl and hydroxy groups at positions 3, 4, and 5 respctively. The disodium salt is the biological stain 'lissamine fast yellow'.


sulcofuron

An organochlorine pesticide consisting of 1,3-diphenylurea having chloro substituents at the 3-, 4- and 5'-positions and a 4-chloro-2-sulfophenoxy group at the 2'-position.


Reactive Blue 5 quinol form

An anthracene that consists of 9,10-dihydroxy-9,10-dihydroanthracene carrying amino, sulfo and [3-({4-chloro-6-[(3-sulfophenyl)amino]-1,3,5-triazin-2-yl}amino)-4-sulfophenyl]amino substituents at positions 1, 2 and 4 respectively.


Reactive red 120

A bis(azo) compound that consists of a benzene core having two (4-amino-6-chloro-1,3,5-triazin-2-yl)amino groups attached at positions 1 and 4 and which in turn have 5-hydroxy-6-[(2-sulfophenyl)diazenyl]-2,7-disulfonaphthalen-4-yl groups attached to their 4-amino functions.


benzenesulfonic acids

An arenesulfonic acid that consists of a benzene ring substituted by at least one sulphonic acid group.


An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.


name: coagulation factor X N-glycosylated 2 (human)

description: A coagulation factor X (human) that has been N-glycosylated at the residue equivalent to Asn-221 of the amino acid sequence represented by UniProtKB:P00742-1, in which the glycan structure is represented by GlyTouCan:G24501HF. Example: UniProtKB:P00742-1, Asn-221, MOD:00160~GNO:G24501HF.


Acute prostatitis

description: An acute inflammatory process that affects the prostate gland.  It is caused by bacteria, most often Escherichia coli, Proteus mirabilis, Klebsiella, and Pseudomonas aeruginosa.


name: interferon gamma isoform 1, signal peptide removed N-glycosylated 1 (human)

description: An interferon gamma isoform 1, signal peptide removed glycosylated form in human in which N-linked glycosylation occurs at Asn-48 and Asn-120. UniProtKB:P01579-1, 24-157, Asn-48/Asn-120, MOD:00160.


name: mothers against decapentaplegic homolog 4 sequence variant Q455* (human)

description: A mothers against decapentaplegic homolog 4 (human) that has has been truncated after the position equivalent to Ala-454 of the amino acid sequence represented by UniProtKB:Q13485. UniProtKB:Q13485, 1-454.


integrin beta-7 isoform Short (human)

An integrin beta-7 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P26010-2.


name: integrin beta-7 isoform 1, signal peptide removed form (human)

description: An integrin beta-7 isoform 1, signal peptide removed form in human. UniProtKB:P26010-1, 20-798.


integrin beta-7 deaminated 1 (human)

An integrin beta-7 (human) that has been deaminated on the residue at the position equivalent to Asn-434 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Asn-434, MOD:00684.


integrin beta-7 isoform 1 (human)

An integrin beta-7 isoform 1 that is encoded in the genome of human.


integrin beta-7 methylated 2 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-537 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-537, MOD:00660.


integrin beta-7 methylated 5 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-271 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-271, MOD:00660.


integrin beta-7 methylated 1 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-654 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-654, MOD:00660.


integrin beta-7 methylated 3 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-670 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-670, MOD:00660.


integrin beta-7 methylated 4 (human)

An integrin beta-7 (human) that has been methylated on the residue at the position equivalent to Cys-448 of the amino acid sequence represented by UniProtKB:P26010-1. Example: UniProtKB:P26010-1, Cys-448, MOD:00660.


name: Sal-like protein 4 isoform hSALL4B (human)

description: A Sal-like protein 4 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9UJQ4-2.


name: leucine-rich repeat LGI family member 4 isoform h2 (human)

description: A leucine-rich repeat LGI family member 4 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8N135-2.


renal hypomagnesemia 4

description: Any primary hypomagnesemia in which the cause of the disease is a mutation in the EGF gene.


serine incorporator 1

A protein that is a translation product of the human SERINC1 gene or a 1:1 ortholog thereof.


name: serine incorporator 1 cysteinylated 1 (human)

description: A serine incorporator 1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-193 of the amino acid sequence represented by UniProtKB:Q9NRX5. UniProtKB:Q9NRX5, Cys-193, MOD:00765.


name: serine incorporator 1 deaminated 1 (human)

description: A serine incorporator 1 (human) that has been deaminated on the residue at the position equivalent to Asn-33 of the amino acid sequence represented by UniProtKB:Q9NRX5. UniProtKB:Q9NRX5, Asn-33, MOD:00684.


serine incorporator 1 isoform 1 (human)

A serine incorporator 1 isoform 1 that is encoded in the genome of human.


name: serine incorporator 1, initiator methionine removed form (human)

description: A serine incorporator 1 (human) that has had the initiator methionine removed. UniProtKB:Q9NRX5, 2-453.


name: NACHT, LRR and PYD domains-containing protein 12 deaminated 1 (human)

description: A NACHT, LRR and PYD domains-containing protein 12 (human) that has been deaminated on the residue at the position equivalent to Asn-780 of the amino acid sequence represented by UniProtKB:P59046-1. Example: UniProtKB:P59046-1, Asn-780, MOD:00684.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 3 in human. UniProtKB:P04049-1, Ser-259/Ser-621, MOD:00046.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 that is encoded in the genome of human.


name: RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 (human)

description: A RAF proto-oncogene serine/threonine-protein kinase isoform 1 phosphorylated 2 in human. UniProtKB:P04049-1, Ser-338/Ser-339, MOD:00046.


name: RAS guanyl-releasing protein 1 isoform h2 (human)

description: A RAS guanyl-releasing protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O95267-2.


name: histone H3.1, initiator methionine removed symmetrically-dimethylated 1 (human)

description: A histone H3.1 (human) that has had the initiator methionine removed and that has been symmetrically-dimethylated on the residue at the position equivalent to Arg-9 of the amino acid sequence represented by UniProtKB:P68431. UniProtKB:P68431, 2-136, Arg-9, MOD:00076.


name: tissue factor pathway inhibitor isoform Beta (human)

description: A tissue factor pathway inhibitor (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P10646-2.


name: serine/Arginine-related protein 53 isoform h2 (human)

description: A serine/Arginine-related protein 53 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96IZ7-2.


name: DNA repair protein complementing XP-C cells isoform h2 (human)

description: A DNA repair protein complementing XP-C cells (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q01831-2.


Hernández-Aguirre Negrete syndrome

description: A syndrome is characterized by major seizures, dysmorphic features (round face, bulbous nose, wide mouth, prominent philtrum), pes planus, psychomotor retardation and obesity. It has been described in five children (three boys and two girls, one of whom died in infancy) from two unrelated Mexican families. This condition is likely to be transmitted as an autosomal recessive trait.


name: F-box/WD repeat-containing protein 1A methylated 1 (human)

description: An F-box/WD repeat-containing protein 1A (human) that has been methylated on the residue at the position equivalent to Cys-137 of the amino acid sequence represented by UniProtKB:Q9Y297-1. Example: UniProtKB:Q9Y297-1, Cys-137, MOD:00660.


name: versican core protein O-glycosylated 117 (human)

description: A versican core protein (human) that has been O-glycosylated at the residue equivalent to Thr-1569 of the amino acid sequence represented by UniProtKB:P13611-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P13611-1, Thr-1569, MOD:00005~GNO:G43417UB.


name: E3 ubiquitin-protein ligase RNF19B isoform h4 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-4.


name: E3 ubiquitin-protein ligase RNF19B deaminated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been deaminated on the residue at the position equivalent to Gln-720 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Gln-720, MOD:00685.


name: E3 ubiquitin-protein ligase RNF19B isoform h1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-1.


name: E3 ubiquitin-protein ligase RNF19B methylated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been methylated on the residue at the position equivalent to Cys-203 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Cys-203, MOD:00660.


name: E3 ubiquitin-protein ligase RNF19B isoform h3 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-3.


name: E3 ubiquitin-protein ligase RNF19B cysteinylated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been cysteinylated on the residue at the position equivalent to Cys-203 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Cys-203, MOD:00765.


name: E3 ubiquitin-protein ligase RNF19B cysteinylated 2 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been cysteinylated on the residue at the position equivalent to Cys-695 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Cys-695, MOD:00765.


name: E3 ubiquitin-protein ligase RNF19B phosphorylated 1 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that has been phosphorylated on the residue at the position equivalent to Ser-270 of the amino acid sequence represented by UniProtKB:Q6ZMZ0-1. Example: UniProtKB:Q6ZMZ0-1, Ser-270, MOD:00046.


name: E3 ubiquitin-protein ligase RNF19B isoform h2 (human)

description: An E3 ubiquitin-protein ligase RNF19B (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6ZMZ0-2.


Pathology Result

category: biolink:PhenotypicFeature biolink:DiseaseOrPhenotypicFeature biolink:BiologicalEntity biolink:ThingWithTaxon biolink:NamedThing

description: The outcome of a pathologic examination.


Atypia

description: The condition of being irregular or not conforming to type.


Large Cell Dysplasia

description: A premalignant neoplastic lesion of the liver.  It is characterized by the presence of hepatocytes with enlarged nuclei and cytoplasm, nuclear pleomorphism, multinucleation, and hyperchromasia.


name: progressive transformation of germinal centers

description: Progressive transformation of germinal centers is a condition in which a lymph node becomes very enlarged (lymphadenopathy). Typically, only one lymph node is affected, though PTGC can involve multiple lymph nodes. Theneck is the most common location of affected lymph nodes, but PTGC may also affect lymph nodes in the groin and armpits. adults are more frequently affected than children, but children have a higher chance of developing PTGC multiple times (recurrence). PTGC is not considered a precancerous condition, though it has been associated with Hodgkin lymphoma.


name: Small Capillary-Sized Vascular Proliferation


Epithelial metaplasia

description: A morphologic finding that refers to the replacement of a group of one type of epithelial cells (e.g., glandular epithelial cells) to another type of epithelial cells (e.g., squamous epithelial cells).


Deposit

description: Accumulation of extraneous inorganic matter in tissues or cavities.


Histopathology Result

description: A finding resulting from the examination of a tissue sample under light or electron microscopy.


Microvascular Proliferation

description: A morphological finding indicating the presence of newly formed blood vessels comprised of smooth muscle cells, pericytes and hyperplastic endothelial cells.


Vascular Endothelial Proliferation

description: A question as to whether vascular endothelial proliferation was present.


Cytologic atypia

description: The presence of irregularly shaped or sized cells as compared to the cells that are normally present.


Necrotic Change

description: A finding indicating the presence of cellular necrosis in a tissue specimen.


Focal Cortical Dysplasia Type 2

description: Focal cortical dysplasia characterized by disrupted cortical lamination and specific cytological abnormalities. It includes type IIa with dysmorphic neurons and type IIb with dysmorphic neurons and balloon cells.


Tuboendometrioid Metaplasia

description: Replacement of the endocervical-type epithelium of the cervix by benign tubal or endometrioid epithelium.


Small Cell Dysplasia

description: A premalignant neoplastic lesion of the liver.  It is characterized by the presence of hepatocytes with decreased cell volume, increased nuclear/cytoplasmic ratio, basophilia, mild nuclear pleomorphism, and hyperchromasia.


Focal Cortical Dysplasia

description: A congenital cortical developmental abnormality characterized by focal architectural distortion of the cortical brain layers. It is associated with the presence of cytologic abnormalities including hypertrophic and dysmorphic neurons. It is caused by genetic or acquired factors and is often associated with epilepsy.


Congenital Dysplasia

description: Abnormal tissue formation due to abnormal cellular organization, which may result in a morphologic defect.


name: Massive Sinusoidal Histiocytic Infiltrate


Metaplasia

description: Transformation of a mature, normal cell or groups of mature cells to other forms of mature cells.  The capacity for malignant transformation of metaplastic cells is a subject of controversy.


Cervical Transitional Metaplasia

description: Cervical metaplasia in which the cervical squamous epithelium resembles benign urothelium as a result of a lack of cellular maturation.


Sinus Histiocytosis

description: A morphologic finding indicating the presence of histiocytic infiltrates within distended lymph node sinuses.


Focal Cortical Dysplasia Type 3

description: Focal cortical dysplasia characterized by different cortical dyslamination and cytological abnormalities with the main lesions located in the same area. It includes the following: type IIIa with architectural distortion of cortical layer in temporal lobe with hippocampal atrophy; type IIIb with architectural distortion of cortical layer adjacent to glial or glioneuronal tumor; type IIIc with architectural distortion of cortical layer adjacent to vascular malformation; and type IIId with architectural distortion of cortical layer adjacent to other lesions acquired in early childhood (e.g., trauma, ischemic event, and encephalitis).


name: Proliferation of High Endothelial Venules Present


Morphologic Finding

description: A light microscopic finding that describes the cellular characteristics and architectural patterns of cell populations in a tissue sample.


Dystrophic Calcification

description: Calcium deposits in  degenerated or necrotic tissue without abnormalities in blood calcium.


name: Microcalcification Present in Neoplastic and Non-Neoplastic Tissue

description: A finding of microcalcifications located within neoplastic tissue, and in tissues without neoplasm.


name: Microcalcification Present in Neoplastic Tissue

description: A finding of microcalcifications located within neoplastic tissue.


Dysplasia

description: A usually neoplastic transformation of the cell, associated with altered architectural tissue patterns. The cellular changes include nuclear and cytoplasmic abnormalities. Molecular genetic abnormalities are also often found and, in some instances, may lead to cancer.


Fibrosis

description: The formation of fibrous tissue.


name: Microcalcification Present in Non-Neoplastic Tissue

description: A finding of microcalcifications located within tissues without neoplasm.


Extraskeletal calcification

description: Deposition of calcium in tissues outside of bone.


Breast Microcalcification

description: Tiny deposits of calcium in tissue.  In the breast they can be seen using mammography, and if found in clusters may be indicative of breast cancer.


Necrotic Lesion

description: A lesion characterized by irreversible damage leading to cellular death.


Focal Cortical Dysplasia Type 1

description: Focal cortical dysplasia characterized by abnormal cortical layering. It is associated with mild symptoms, late onset, and changes present in the temporal lobe. It includes the following: type Ia with abnormal radial migration and maturation of neurons; type Ib with disruption of the six-layered tangential composition of the cortex with immature neurons; and type Ic comprising both architectural abnormalities.


Squamous metaplasia of cervix

description: The process in which the cervical glandular epithelium is replaced with squamous epithelium.


Fatty degeneration

description: Acumulation of adipose tissue in intracytoplasmic or extracellular spaces.


name: proteinase-activated receptor 1 deaminated 1 (human)

description: A proteinase-activated receptor 1 (human) that has been deaminated on the residue at the position equivalent to Asn-75 of the amino acid sequence represented by UniProtKB:P25116. UniProtKB:P25116, Asn-75, MOD:00684.


name: proteinase-activated receptor 1, signal peptide removed form (human)

description: A proteinase-activated receptor 1 (human) that has had the signal peptide removed. UniProtKB:P25116, 22-425.


name: Refractory Malignant Gastrointestinal Stromal Tumor

description: Malignant gastrointestinal stromal tumor that is resistant to treatment.


Refractory Soft Tissue Sarcoma

description: A soft tissue sarcoma that does not respond to treatment.


Refractory Epithelioid Sarcoma

description: An epithelioid sarcoma that does not respond to treatment.


Refractory Synovial Sarcoma

description: Synovial sarcoma that does not respond to treatment.


name: Refractory Extraskeletal Myxoid Chondrosarcoma

description: Extraskeletal myxoid chondrosarcoma that does not respond to treatment.


name: Refractory Undifferentiated Pleomorphic Sarcoma

description: Undifferentiated pleomorphic sarcoma that does not respond to treatment.


Refractory Alveolar Rhabdomyosarcoma

description: Alveolar rhabdomyosarcoma that does not respond to treatment.


Refractory Kaposi Sarcoma

description: Kaposi sarcoma that is resistant to treatment.


Refractory Alveolar Soft Part Sarcoma

description: Alveolar soft part sarcoma that is resistant to treatment.


name: Refractory Childhood Soft Tissue Sarcoma

description: Childhood soft tissue sarcoma that is resistant to treatment.


name: Refractory Desmoplastic Small Round Cell Tumor

description: Desmoplastic small round cell tumor that is resistant to treatment.


Refractory Childhood Rhabdomyosarcoma

description: Childhood rhabdomyosarcoma that is resistant to treatment.


Refractory Rhabdomyosarcoma

description: Rhabdomyosarcoma that does not respond to treatment.


2'-deoxyguanosine 3'-monophosphate

A deoxyguanosine phosphate having a monophosphate group located at the 3'-position.


2'-deoxyadenosine 3'-monophosphate

A 2'-deoxyadenosine phosphate having a monophosphate group located at the 3'-position.


A pyrimidine 2'-deoxyribonucleoside 3'-monophosphate that is the mono-(5-bromo-4-chloro-indol-3-yl) ester of thymidine 3'-phosphate.


2'-deoxyuridine 3'-monophosphate

A pyrimidine 2'-deoxyribonucleoside 3'-monophosphate having uracil as the nucleobase.


thymidine 3'-monophosphate

A pyrimidine 2'-deoxyribonucleoside 3'-monophosphate having thymine as the nucleobase.


epiphyseal dysplasia, multiple, 3

description: Any multiple epiphyseal dysplasia in which the cause of the disease is a mutation in the COL9A3 gene.


orbit embryonal rhabdomyosarcoma

description: A malignant mesenchymal neoplasm that arises from the orbit. It is characterized by the presence of skeletal muscle tissue exhibiting embryonic features.


Metastatic embryonal rhabdomyosarcoma

description: Embryonal rhabdomyosarcoma that has spread from its original site of growth to another anatomic site.


Middle Ear Embryonal Rhabdomyosarcoma

description: A rare embryonal rhabdomyosarcoma that arises in the middle ear.


name: adult vagina botryoid embryonal rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma arising from the vagina. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma. It occurs in female adults.


adult botryoid rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in adults. The neoplasm arises from organs containing a mucosal epithelial surface. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma.


name: childhood vagina botryoid rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in female children. The neoplasm arises from the vagina. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma.


embryonal rhabdomyosarcoma of bladder

description: An embryonal rhabdomyosarcoma arising from the bladder. It is the most common type of rhabdomyosarcoma of the bladder affecting young children.


prostate embryonal rhabdomyosarcoma

description: A malignant mesenchymal neoplasm of the prostate. It is characterized by the presence of skeletal muscle exhibiting embryonic features.


Anaplastic embryonal rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma.  It is characterized by the presence of large hyperchromatic and anaplastic cells.


name: vulvar childhood botryoid-type embryonal rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in female children. The neoplasm arises from the vulva. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules with an abundant myxoid stroma.


childhood botryoid rhabdomyosarcoma

description: A morphologic variant of embryonal rhabdomyosarcoma occurring in children. The tumor arises from organs with a mucosal epithelial surface. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.


name: botryoid-type embryonal rhabdomyosarcoma of the vagina

description: A morphologic variant of embryonal rhabdomyosarcoma arising from the vagina. It is characterized by the formation of a cambium layer in the affected tissue and polypoid nodules within an abundant myxoid stroma.


Childhood Embryonal Rhabdomyosarcoma

description: A poorly circumscribed morphologic variant of rhabdomyosarcoma occurring in children.  The neoplasm is characterized by the presence of primitive skeletal muscle in any stage of myogenesis.


sororin phosphorylated 1 (human)

A sororin (human) that has been post-translationally modified to include phosphoserine at positions 21 and 75, and phosphothreonine at position 159 of the amino acid sequence represented by UniProtKB:Q96FF9. UniProtKB:Q96FF9, Ser-21/Ser-75, MOD:00046|Thr-159, MOD:00047.


name: LIM domain-containing protein 2 cysteinylated 2 (human)

description: A LIM domain-containing protein 2 (human) that has been cysteinylated on the residue at the position equivalent to Cys-88 of the amino acid sequence represented by UniProtKB:Q9BT23. UniProtKB:Q9BT23, Cys-88, MOD:00765.


plexin-C1 N-glycosylated 7 (human)

A plexin-C1 (human) that has been N-glycosylated at the residue equivalent to Asn-871 of the amino acid sequence represented by UniProtKB:O60486-1, in which the glycan composition is represented by GlyTouCan:G98208DX. Example: UniProtKB:O60486-1, Asn-871, MOD:00160~GNO:G98208DX.


name: ATP-binding cassette sub-family D member 1 sequence variant R617C (human)

description: An ATP-binding cassette sub-family D member 1 (human) that has a Cys residue at the position equivalent to Arg-617 of the amino acid sequence represented by UniProtKB:P33897. UniProtKB:P33897, Arg-617, CHEBI:29950.


name: E3 ubiquitin-protein ligase RNF34 isoform h1 (human)

description: An E3 ubiquitin-protein ligase RNF34 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q969K3-1.


name: Stage 0 Lip Basal Cell Carcinoma AJCC v6 and v7


La-related protein 1

A protein that is a translation product of the human LARP1 gene or a 1:1 ortholog thereof.


La-related protein 1 isoform h1 (human)

A La-related protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6PKG0-1.


name: La-related protein 1, initiator methionine removed form (human)

description: A La-related protein 1 (human) that has had the initiator methionine removed. Example: UniProtKB:Q6PKG0-1, 2-1096.


La-related protein 1 isoform h2 (human)

A La-related protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q6PKG0-3.


name: La-related protein 1 phosphorylated 1 (human)

description: A La-related protein 1 (human) that has been phosphorylated on the residue at the position equivalent to Thr-526 of the amino acid sequence represented by UniProtKB:Q6PKG0-1. Example: UniProtKB:Q6PKG0-1, Thr-526, MOD:00047.


Atypical cartilaginous tumor

description: A locally aggressive, low grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma in the appendicular skeleton.


Central Atypical Cartilaginous Tumor

description: A locally aggressive, low-grade chondrosarcoma arising in the medulla of bone in the appendicular skeleton.


name: Secondary Peripheral Atypical Cartilaginous Tumor

description: A locally aggressive, low-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma in the appendicular skeleton.


cortistatin D

A member of the class of cortistatins that is cortistatin C in which the hydrogen at position 17 has been replaced by a hydroxy group.


cortistatins

Any member of a class of steroidal alkaloids obtained from the marine sponge Corticium simplex, with a basic skeleton that is (5R,8beta)-5,8-epoxy-9,19-cyclo-9,10-secoandrostane, bearing a dimethylamino substituent at position 3 and an isoquinolin-7-yl or isoquinolin-7-yl-derived substituent at position 17. They selectively inhibit proliferation of human umbilical vein endothelial cells (HUVECs).


HOOKERIANAMIDE H

A steroid alkaloid that is 5alpha-pregn-2-ene-4-one substituted by a N-formylamino group at position 3 and a N,N-dimethylamino group at position 20. Isolated from Sarcococca hookeriana, it exhibits antiplasmodial activity and inhibitory activity against cholinesterase.


HOOKERIANAMIDE J

A steroid alkaloid that is 5alpha-preg-16-ene substituted by a hydroxy group at position 4, a N,N-dimethylamino group at position 20 and a N-senecoylamino group at position 3 (the 3beta,4beta,20S stereoisomer). Isolated from Sarcococca hookeriana, it exhibits antileishmanial and antibacterial activities.


cortistatin C

A member of the class of cortistatins that is cortistatin A in which the hydrogens at position 16 have been replaced by an oxo group.


cortistatin B

A member of the class of cortistatins that is cortistatin A in which the hydrogen at the 16beta position has been replaced by a hydroxy group.


Stage IIIa Penile Cancer AJCC v7

description: Stage IIIa includes: T1-3, N1, M0.  T1: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4) or tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN1: Palpable mobile unilateral inguinal lymph node.  pN1: Metastasis in a single inguinal lymph node.  M0: No distant metastasis. (AJCC 7th ed.)


Penile Cancer by AJCC v7 Stage

description: A term that refers to the staging of penile carcinoma according to the American Joint Committee on Cancer, 7th edition.


Stage IIIb Penile Cancer AJCC v7

description: Stage IIIb includes: T1-3, N2, M0.  T1: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4) or tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN2: Palpable mobile multiple or bilateral inguinal lymph nodes. pN2: Metastasis in multiple or bilateral superficial inguinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage IV Penile Cancer AJCC v7

description: Stage IV includes: (T4, Any N, M0); (Any T, N3, M0); (Any T, Any N, M1).  T4: Tumor invades other adjacent structures.  cN3: Palpable fixed inguinal nodal mass or pelvic lymphadenopathy unilateral or bilateral.  pN3: Extranodal extension of lymph node metastasis or pelvic lymph node(s) unilateral or bilateral.  M0: No distant metastasis. M1: Distant metastasis (lymph node metastasis outside of the true pelvis in addition to visceral or bone sites).  (AJCC 7th ed.)


Stage II Penile Cancer AJCC v7

description: Stage II includes: (T1b, N0, M0); (T2, N0, M0); (T3, N0, M0).  T1b: Tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


Stage I Penile Cancer AJCC v7

description: Stage I includes: T1a, N0, M0.  T1a: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4).  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis.  (AJCC 7th ed.)


Stage III Penile Cancer AJCC v7

description: Stage III includes: IIIa (T1-3, N1, M0); IIIb (T1-3, N2, M0).  T1: Tumor invades subepithelial connective tissue without lymph vascular invasion and is not poorly differentiated (i.e., grade 3-4) or tumor invades subepithelial connective tissue with lymph vascular invasion or is poorly differentiated.  T2: Tumor invades corpus spongiosum or cavernosum.  T3: Tumor invades urethra.  cN1: Palpable mobile unilateral inguinal lymph node.  pN1: Metastasis in a single inguinal lymph node.  cN2: Palpable mobile multiple or bilateral inguinal lymph nodes. pN2: Metastasis in multiple or bilateral superficial inguinal lymph nodes.  M0: No distant metastasis. (AJCC 7th ed.)


Stage 0 Penile Cancer AJCC v7

description: Stage 0 includes: (Tis, N0, M0); (Ta, N0, M0).  Tis: Carcinoma in situ.  Ta: Non-invasive verrucous carcinoma.  cN0: No palpable or visibly enlarged inguinal lymph nodes.  pN0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)


name: striated muscle preferentially expressed protein kinase isoform h3 (human)

description: A striated muscle preferentially expressed protein kinase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q15772-4.


name: striated muscle preferentially expressed protein kinase isoform h2 (human)

description: A striated muscle preferentially expressed protein kinase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q15772-3.


name: striated muscle preferentially expressed protein kinase isoform h1 (human)

description: A striated muscle preferentially expressed protein kinase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q15772-1.


name: striated muscle preferentially expressed protein kinase isoform h4 (human)

description: A striated muscle preferentially expressed protein kinase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q15772-5.


name: immunoglobulin heavy constant delta O-glycosylated 2 (human)

description: An immunoglobulin heavy constant delta (human) that has been O-glycosylated at the residue equivalent to Thr-113 of the amino acid sequence represented by UniProtKB:P01880-2, in which the glycan composition is represented by GlyTouCan:G29068FM. Example: UniProtKB:P01880-2, Thr-113, MOD:00005~GNO:G29068FM.


name: microfibrillar-associated protein 2 isoform A' (human)

description: A microfibrillar-associated protein 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P55001-2.


L-threo-isocitric acid

The (1S,2R)-stereoisomer of isocitric acid.


A 1,2-diacyl-sn-glycerol in which the 1-acyl group is specified as oleoyl.


calponin-2 deaminated 1 (human)

A calponin-2 (human) that has been deaminated on the residue at the position equivalent to Gln-248 of the amino acid sequence represented by UniProtKB:Q99439-1. Example: UniProtKB:Q99439-1, Gln-248, MOD:00685.


name: macular coloboma-cleft palate-hallux valgus syndrome

description: Macular coloboma-cleft palate-hallux valgus syndrome is characterized by the association of bilateral macular coloboma, cleft palate, and hallux valgus. It has been described in a brother and sister. Pelvic, limb and digital anomalies were also reported. Transmission is autosomal recessive.


2-acylglycerol 22:4

A 2-monoglyceride in which the acyl group contains 22 carbons and 4 double bonds.


monoacylglycerol 22:4

A monoglyceride in which the acyl groups contain a total of 22 carbons and 4 double bonds


1-acylglycerol 22:4

A 1-monoglyceride in which the acyl group contains 22 carbons and 4 double bonds.


name: basic helix-loop-helix ARNT-like protein 2 isoform h3 (human)

description: A basic helix-loop-helix ARNT-like protein 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8WYA1-3.


name: immunoglobulin heavy constant mu isoform h1 N-glycosylated 70 (human)

description: An immunoglobulin heavy constant mu isoform h1 (human) that has been N-glycosylated at the residue equivalent to Asn-440 of the amino acid sequence represented by UniProtKB:P01871-1, in which the glycan composition is represented by GlyTouCan:G41247ZX. UniProtKB:P01871-1, Asn-440, MOD:00160~GNO:G41247ZX.


name: mediator of RNA polymerase II transcription subunit 28 isoform 1 (human)

description: A mediator of RNA polymerase II transcription subunit 28 isoform 1 that is encoded in the genome of human.


name: mediator of RNA polymerase II transcription subunit 28 isoform 1 phosphorylated 1 (human)

description: A mediator of RNA polymerase II transcription subunit 28 isoform 1 phosphorylated 1 in human. UniProtKB:Q9H204-1, Tyr-64, MOD:00048.


name: sterol regulatory element-binding protein 1 isoform hSREBP-1C (human)

description: A sterol regulatory element-binding protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P36956-3.


A sulfoglycolipid in which alpha,alpha-trehalose, sulfated at the 2'-position, is acylated at the 2-position with palmitic acid, and at the 3-position with (2E)-2-methylicos-2-enoic acid.


name: versican core protein O-glycosylated 219 (human)

description: A versican core protein (human) that has been O-glycosylated at the residue equivalent to Thr-2887 of the amino acid sequence represented by UniProtKB:P13611-1, in which the glycan composition is represented by GlyTouCan:G43417UB. Example: UniProtKB:P13611-1, Thr-2887, MOD:00005~GNO:G43417UB.


name: collagen alpha-2(XI) chain isoform 5 (human)

description: A collagen alpha-2(XI) chain isoform 5 that is encoded in the genome of human.


name: ATP-dependent RNA helicase A deaminated 3 (human)

description: An ATP-dependent RNA helicase A (human) that has been deaminated on the residue at the position equivalent to Asn-311 of the amino acid sequence represented by UniProtKB:Q08211-1. Example: UniProtKB:Q08211-1, Asn-311, MOD:00684.


protein bicaudal D homolog 2

A protein that is a translation product of the human BICD2 gene or a 1:1 ortholog thereof.


name: protein bicaudal D homolog 2 deaminated 2 (human)

description: A protein bicaudal D homolog 2 (human) that has been deaminated on the residue at the position equivalent to Asn-293 of the amino acid sequence represented by UniProtKB:Q8TD16-1. Example: UniProtKB:Q8TD16-1, Asn-293, MOD:00684.


name: protein bicaudal D homolog 2 deaminated 1 (human)

description: A protein bicaudal D homolog 2 (human) that has been deaminated on the residue at the position equivalent to Asn-700 of the amino acid sequence represented by UniProtKB:Q8TD16-1. Example: UniProtKB:Q8TD16-1, Asn-700, MOD:00684.


name: protein bicaudal D homolog 2 isoform h2 (human)

description: A protein bicaudal D homolog 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8TD16-2.


name: protein bicaudal D homolog 2 isoform h1 (human)

description: A protein bicaudal D homolog 2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8TD16-1.


name: protein bicaudal D homolog 2 deaminated 3 (human)

description: A protein bicaudal D homolog 2 (human) that has been deaminated on the residue at the position equivalent to Gln-351 of the amino acid sequence represented by UniProtKB:Q8TD16-1. Example: UniProtKB:Q8TD16-1, Gln-351, MOD:00685.


name: nuclear autoantigen Sp-100 cysteinylated 1 (human)

description: A nuclear autoantigen Sp-100 (human) that has been cysteinylated on the residue at the position equivalent to Cys-629 of the amino acid sequence represented by UniProtKB:P23497-1. Example: UniProtKB:P23497-1, Cys-629, MOD:00765.


protein TESPA1 isoform h3 (human)

A protein TESPA1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:A2RU30-3.


SLIT and NTRK-like protein 1

A protein that is a translation product of the human SLITRK1 gene or a 1:1 ortholog thereof.


name: SLIT and NTRK-like protein 1, signal peptide removed form (human)

description: A SLIT and NTRK-like protein 1 (human) that has had the signal peptide removed. UniProtKB:Q96PX8, 18-696.


name: SLIT and NTRK-like protein 1 isoform 1 (human)

description: A SLIT and NTRK-like protein 1 isoform 1 that is encoded in the genome of human.


Neuroma of amputation stump

description: A neuroma that occurs at the site of an amputation.


Traumatic neuroma

description: A non-neoplastic proliferation of a nerve caused by injury to the nerve due to trauma or surgery. It presents as a firm nodule that may be associated with pain or tenderness. It most often occurs in the lower extremity following amputation, or in the head and neck region.


Appendix Neuroma

description: A neuroma that arises from the appendix.  It is characterized by a neural spindle cell proliferation that replaces the appendiceal mucosa and lymphoid tissue.  It usually results in the obliteration of the appendiceal lumen.


name: E3 ubiquitin-protein ligase makorin-1 phosphorylated 1 (human)

description: An E3 ubiquitin-protein ligase makorin-1 (human) that has been phosphorylated on the residue at the position equivalent to Ser-109 of the amino acid sequence represented by UniProtKB:Q9UHC7-1. Example: UniProtKB:Q9UHC7-1, Ser-109, MOD:00046.


name: low-density lipoprotein receptor, signal peptide removed form (human)

description: A low-density lipoprotein receptor (human) that has had the signal peptide removed. UniProtKB:P01130, 22-860.


name: TGF-beta receptor type-2 sequence variant N435S (human)

description: A TGF-beta receptor type-2 (human) that has a Ser residue at the position equivalent to Asn-435 of the amino acid sequence represented by UniProtKB:P37173-1. Example: UniProtKB:P37173-1, Asn-435, CHEBI:29999.


name: diacylglycerol kinase delta isoform h2 (human)

description: A diacylglycerol kinase delta (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q16760-1.


name: sodium-dependent neutral amino acid transporter B(0)AT1 sequence variant D173N (human)

description: A sodium-dependent neutral amino acid transporter B(0)AT1 (human) that has an Asn residue at the position equivalent to Asp-173 of the amino acid sequence represented by UniProtKB:Q695T7. UniProtKB:Q695T7, Asp-173, CHEBI:50347.


name: sodium-dependent neutral amino acid transporter B(0)AT1 sequence variant S303L (human)

description: A sodium-dependent neutral amino acid transporter B(0)AT1 (human) that has a Leu residue at the position equivalent to Ser-303 of the amino acid sequence represented by UniProtKB:Q695T7. UniProtKB:Q695T7, Ser-303, CHEBI:30006.


name: sodium-dependent neutral amino acid transporter B(0)AT1 isoform 1 (human)

description: A sodium-dependent neutral amino acid transporter B(0)AT1 isoform 1 that is encoded in the genome of human.


name: GATOR1 complex protein NPRL2 deaminated 1 (human)

description: A GATOR1 complex protein NPRL2 (human) that has been deaminated on the residue at the position equivalent to Gln-338 of the amino acid sequence represented by UniProtKB:Q8WTW4-1. Example: UniProtKB:Q8WTW4-1, Gln-338, MOD:00685.


GATOR1 complex protein NPRL2

A protein that is a translation product of the human NPRL2 gene or a 1:1 ortholog thereof.


name: GATOR1 complex protein NPRL2 isoform h2 (human)

description: A GATOR1 complex protein NPRL2 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8WTW4-2.


name: GATOR1 complex protein NPRL2 isoform 1 (human)

description: A GATOR1 complex protein NPRL2 isoform 1 that is encoded in the genome of human.


hereditary spherocytosis type 3

description: Any hereditary spherocytosis in which the cause of the disease is a mutation in the SPTA1 gene.


name: immunoglobulin heavy constant mu N-glycosylated 30 (human)

description: An immunoglobulin heavy constant mu (human) that has been N-glycosylated at the residue equivalent to Asn-272 of the amino acid sequence represented by UniProtKB:P01871-2, in which the glycan composition is represented by GlyTouCan:G12580WI. Example: UniProtKB:P01871-2, Asn-272, MOD:00160~GNO:G12580WI.


name: ribosomal protein S6 kinase delta-1 isoform h1 (human)

description: A ribosomal protein S6 kinase delta-1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96S38-1.


name: ribosomal protein S6 kinase delta-1 isoform h2 (human)

description: A ribosomal protein S6 kinase delta-1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96S38-2.


Nasopharyngeal Squamous Papilloma

description: A benign exophytic neoplasm that arises from the nasopharynx.  It is characterized by the presence of a connective tissue core covered by stratified squamous epithelium.


name: DNA repair protein RAD51 homolog 3 methylated 2 (human)

description: A DNA repair protein RAD51 homolog 3 (human) that has been methylated on the residue at the position equivalent to Cys-124 of the amino acid sequence represented by UniProtKB:O43502-1. Example: UniProtKB:O43502-1, Cys-124, MOD:00660.


name: disintegrin and metalloproteinase domain-containing protein 21

description: A protein that is a translation product of the human ADAM21 gene or a 1:1 ortholog thereof.


name: disintegrin and metalloproteinase domain-containing protein 21 methylated 1 (human)

description: A disintegrin and metalloproteinase domain-containing protein 21 (human) that has been methylated on the residue at the position equivalent to Cys-565 of the amino acid sequence represented by UniProtKB:Q9UKJ8. UniProtKB:Q9UKJ8, Cys-565, MOD:00660.


name: neurogenic differentiation factor 6 isoform 1 (human)

description: A neurogenic differentiation factor 6 isoform 1 that is encoded in the genome of human.


name: ankyrin repeat domain-containing protein 10 isoform h2 (human)

description: An ankyrin repeat domain-containing protein 10 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NXR5-2.


name: ankyrin repeat domain-containing protein 10 methylated 2 (human)

description: An ankyrin repeat domain-containing protein 10 (human) that has been methylated on the residue at the position equivalent to Cys-183 of the amino acid sequence represented by UniProtKB:Q9NXR5-1. Example: UniProtKB:Q9NXR5-1, Cys-183, MOD:00660.


name: ankyrin repeat domain-containing protein 10 deaminated 2 (human)

description: An ankyrin repeat domain-containing protein 10 (human) that has been deaminated on the residue at the position equivalent to Asn-195 of the amino acid sequence represented by UniProtKB:Q9NXR5-1. Example: UniProtKB:Q9NXR5-1, Asn-195, MOD:00684.


name: ankyrin repeat domain-containing protein 10 methylated 1 (human)

description: An ankyrin repeat domain-containing protein 10 (human) that has been methylated on the residue at the position equivalent to Cys-107 of the amino acid sequence represented by UniProtKB:Q9NXR5-1. Example: UniProtKB:Q9NXR5-1, Cys-107, MOD:00660.


name: ankyrin repeat domain-containing protein 10 deaminated 1 (human)

description: An ankyrin repeat domain-containing protein 10 (human) that has been deaminated on the residue at the position equivalent to Asn-85 of the amino acid sequence represented by UniProtKB:Q9NXR5-1. Example: UniProtKB:Q9NXR5-1, Asn-85, MOD:00684.


name: ankyrin repeat domain-containing protein 10 cysteinylated 1 (human)

description: An ankyrin repeat domain-containing protein 10 (human) that has been cysteinylated on the residue at the position equivalent to Cys-183 of the amino acid sequence represented by UniProtKB:Q9NXR5-1. Example: UniProtKB:Q9NXR5-1, Cys-183, MOD:00765.


name: ankyrin repeat domain-containing protein 10 isoform h1 (human)

description: An ankyrin repeat domain-containing protein 10 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NXR5-1.


name: claudin domain-containing protein 1 deaminated 3 (human)

description: A claudin domain-containing protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-72 of the amino acid sequence represented by UniProtKB:Q9NY35-1. Example: UniProtKB:Q9NY35-1, Asn-72, MOD:00684.


name: claudin domain-containing protein 1 isoform h2 (human)

description: A claudin domain-containing protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NY35-2.


name: claudin domain-containing protein 1 isoform h1 (human)

description: A claudin domain-containing protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NY35-1.


name: claudin domain-containing protein 1 deaminated 4 (human)

description: A claudin domain-containing protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-124 of the amino acid sequence represented by UniProtKB:Q9NY35-1. Example: UniProtKB:Q9NY35-1, Asn-124, MOD:00684.


name: claudin domain-containing protein 1 cysteinylated 1 (human)

description: A claudin domain-containing protein 1 (human) that has been cysteinylated on the residue at the position equivalent to Cys-106 of the amino acid sequence represented by UniProtKB:Q9NY35-1. Example: UniProtKB:Q9NY35-1, Cys-106, MOD:00765.


name: claudin domain-containing protein 1 deaminated 2 (human)

description: A claudin domain-containing protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-207 of the amino acid sequence represented by UniProtKB:Q9NY35-1. Example: UniProtKB:Q9NY35-1, Asn-207, MOD:00684.


name: claudin domain-containing protein 1 deaminated 1 (human)

description: A claudin domain-containing protein 1 (human) that has been deaminated on the residue at the position equivalent to Asn-126 of the amino acid sequence represented by UniProtKB:Q9NY35-1. Example: UniProtKB:Q9NY35-1, Asn-126, MOD:00684.


name: claudin domain-containing protein 1 methylated 1 (human)

description: A claudin domain-containing protein 1 (human) that has been methylated on the residue at the position equivalent to Cys-139 of the amino acid sequence represented by UniProtKB:Q9NY35-1. Example: UniProtKB:Q9NY35-1, Cys-139, MOD:00660.


name: claudin domain-containing protein 1 isoform h3 (human)

description: A claudin domain-containing protein 1 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q9NY35-3.


name: claudin domain-containing protein 1 methylated 2 (human)

description: A claudin domain-containing protein 1 (human) that has been methylated on the residue at the position equivalent to Cys-106 of the amino acid sequence represented by UniProtKB:Q9NY35-1. Example: UniProtKB:Q9NY35-1, Cys-106, MOD:00660.


phosphopentomutase isoform h1 (human)

A phosphopentomutase (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q96G03-1.


name: krueppel-like factor 4 isoform h2 (human)

description: A krueppel-like factor 4 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:O43474-1.


name: zinc finger protein GLIS3 isoform h2 (human)

description: A zinc finger protein GLIS3 (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:Q8NEA6-2.


name: nuclear mitotic apparatus protein 1 phosphorylated 2 (human)

description: A nuclear mitotic apparatus protein 1 (human) that has been phosphorylated on the residue at the position equivalent to Thr-2055 of the amino acid sequence represented by UniProtKB:Q14980-1. Example: UniProtKB:Q14980-1, Thr-2055, MOD:00047.


Locally Advanced Chondrosarcoma

description: Chondrosarcoma that has spread to nearby tissues or lymph nodes.


pediatric mesenchymal chondrosarcoma

description: A mesenchymal chondrosarcoma occurring in children.


synovial chondrosarcoma of joint

description: An extremely rare chondrosarcoma arising from the synovium either as a de novo neoplasm or secondary to synovial chondromatosis.


Central Chondrosarcoma, Grade 2

description: An intermediate-grade chondrosarcoma arising in the medulla of bone.


Maxillofacial Chondrosarcoma

description: A chondrosarcoma that arises in a maxillofacial bone.


name: Central Nervous System Mesenchymal Chondrosarcoma

description: A mesenchymal chondrosarcoma that arises from the central nervous system.


Chondrosarcoma, Grade 1

description: A locally aggressive, low grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma in the axial skeleton.


Chondrosarcoma, grade 2

description: An intermediate-grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma. It is characterized by the presence of increased cellularity and a greater degree of nuclear atypia and hyperchromasia as compared to grade 1 chondrosarcoma. Mitotic activity is present.


name: Secondary Peripheral Chondrosarcoma, Grade 3

description: A high-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma.


Central Chondrosarcoma, Grade 3

description: A high-grade chondrosarcoma arising in the medulla of bone.


name: Secondary Peripheral Atypical Cartilaginous Tumor/Chondrosarcoma, Grade 1

description: A locally aggressive, low-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma. Tumors in the appendicular skeleton are called peripheral atypical cartilaginous tumors and tumors in the axial skeleton are called peripheral chondrosarcomas, grade 1.


Childhood Chondrosarcoma

description: A rare chondrosarcoma that occurs during childhood.


name: Unresectable Primary Central Chondrosarcoma

description: Primary central chondrosarcoma that is not amenable to surgical resection.


name: Locally Advanced Unresectable Primary Central Chondrosarcoma

description: A primary central chondrosarcoma that has spread from its original site of growth to nearby tissues and is not amenable to surgical resection.


localized chondrosarcoma

description: A non-disseminated skeletal or extraskeletal chondrosarcoma.


name: Childhood Primary Central Chondrosarcoma

description: A rare primary central chondrosarcoma that occurs during childhood.


description: A mesenchymal chondrosarcoma that arises in a maxillofacial bone.


Chondrosarcoma recurrent

description: The reemergence of chondrosarcoma after a period of remission.


Chondrosarcoma, grade 3

description: A high-grade chondrosarcoma arising in the medulla of bone or within the cartilaginous cap of a pre-existing osteochondroma. It is characterized by the presence of increased cellularity and a greater degree of nuclear atypia, hyperchromasia, and mitotic activity as compared to grade 2 chondrosarcoma.


Secondary Peripheral Chondrosarcoma

description: A chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma.


periosteal chondrosarcoma

description: A chondrosarcoma arising from the surface of bone. It is characterized by a lobulated growth pattern, high mitotic activity, myxoid stroma formation, and necrotic changes. It occurs in adults. Clinical presentation includes pain, and sometimes swelling.


name: Secondary Central Atypical Cartilaginous Tumor/Chondrosarcoma, Grade 1

description: Central atypical cartilaginous tumor/chondrosarcoma, grade 1 arising in the medulla of bone in association with a pre-existing enchondroma.


Laryngeal chondrosarcoma

description: A chondrosarcoma that arises from hyaline cartilage of the larynx.


Secondary Chondrosarcoma

description: A chondrosarcoma that arises either in a pre-existing enchondroma or within the cartilaginous cap of a pre-existing osteochondroma.


name: Central Atypical Cartilaginous Tumor/Chondrosarcoma, Grade 1

description: A locally aggressive, low-grade chondrosarcoma arising in the medulla of bone. Tumors in the appendicular skeleton are called central atypical cartilaginous tumors and tumors in the axial skeleton are called central chondrosarcomas, grade 1. Tumors arising in the medulla of the bone without a benign precursor are called primary central atypical cartilaginous tumors/chondrosarcomas, grade 1. Tumors arising in the medulla of the bone in association with a pre-existing enchondroma are called secondary central atypical cartilaginous tumors/chondrosarcomas, grade 1.


clear cell chondrosarcoma

description: A rare, usually low grade chondrosarcoma characterized by the presence of tumor cells with clear cytoplasm. It usually arises in the epiphyseal ends of long bones.


Secondary Central Chondrosarcoma

description: A chondrosarcoma that arises in a pre-existing enchondroma.


name: Metastatic Primary Central Chondrosarcoma

description: Primary central chondrosarcoma that has spread from its original site of growth to other anatomic sites.


name: Secondary Peripheral Chondrosarcoma, Grade 1

description: A locally aggressive, low-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma in the axial skeleton.


name: Secondary Peripheral Chondrosarcoma, Grade 2

description: An intermediate-grade chondrosarcoma arising within the cartilaginous cap of a pre-existing osteochondroma.


Chondrosarcoma metastatic

description: A chondrosarcoma that has spread to a secondary anatomical site.


Central Chondrosarcoma, Grade 1

description: A locally aggressive, low-grade chondrosarcoma arising in the medulla of bone in the axial skeleton.


name: Atypical Cartilaginous Tumor/Chondrosarcoma, Grade 1

description: A low-grade chondrosarcoma characterized by the presence of moderate cellularity, hyperchromatic and plump nuclei of uniform size, and occasional binucleated cells.  Mitotic figures are absent.


name: Primary Central Atypical Cartilaginous Tumor/Chondrosarcoma, Grade 1

description: Central atypical cartilaginous tumor/chondrosarcoma, grade 1 arising in the medulla of bone without a benign precursor.


mesenchymal chondrosarcoma of bone

description: A morphologic variant of chondrosarcoma arising from the bone.  It is characterized by the presence of malignant small round cells, biphasic growth pattern, and well differentiated hyaline cartilage. Clinical presentation includes pain and swelling.  The clinical course is aggressive, with local recurrences and distant metastases.


adult mesenchymal chondrosarcoma

description: A mesenchymal chondrosarcoma occurring in adults.


proepiregulin methylated 1 (human)

A proepiregulin (human) that has been methylated on the residue at the position equivalent to Cys-11 of the amino acid sequence represented by UniProtKB:O14944. UniProtKB:O14944, Cys-11, MOD:00660.


cathepsin S isoform h1 (human)

A cathepsin S (human) that is a translation product of some mRNA whose exon structure and start site selection renders it capable of giving rise to a protein with the amino acid sequence represented by UniProtKB:P25774-1.


name: proto-oncogene tyrosine-protein kinase Src phosphorylated 1 (human)

description: A proto-oncogene tyrosine-protein kinase Src (human) that has been phosphorylated on the residue at the position equivalent to Ser-75 of the amino acid sequence represented by UniProtKB:P12931-1. Example: UniProtKB:P12931-1, Ser-75, MOD:00046.


name: ribosomal protein S6 kinase alpha-3 phosphorylated 4 (human)

description: A ribosomal protein S6 kinase alpha-3 (human) that has been phosphorylated on the residue at the position equivalent to Ser-227 of the amino acid sequence represented by UniProtKB:P51812. UniProtKB:P51812, Ser-227, MOD:00046.